gray baby syndrome
Enable an AI agent to recognise suspected gray baby syndrome, assess exposure and clinical deterioration, and support timely clinician-led escalation while preserving diagnostic uncertainty.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 16 findings · 26 questions
Syndrome identity and boundaries Defines what constitutes the chloramphenicol-associated syndrome and how its identity is represented.
Clinical concept
Establishes the syndrome's exposure-dependent meaning.
Case definition basis
Record the definition used, its issuing source and whether it is descriptive or formally validated.
- What exposure and clinical evidence does the cited definition require for gray baby syndrome? definition
- Does the definition specify neonatal age limits, and how are reports outside those limits handled? boundary
Diagnosis and coding
Separates syndrome identity from clinical assertions and administrative coding.
Versioned diagnostic assertion
Attach assessor, date, confidence and verified terminology metadata to each diagnostic assertion.
- Who attributed the presentation to gray baby syndrome, using which evidence and assessment method? provenance
- Which verified ICD or SNOMED release represents this syndrome, and does the mapping denote the syndrome itself or a broader drug-related event? boundary
Exposure and accumulation Reconstructs chloramphenicol exposure and factors relevant to excessive concentrations.
Administration history
Reconciles prescribed, prepared and administered exposure.
Reconstructed drug exposure
Record formulation, route, actual doses, intervals, weight basis and evidence for any indirect exposure.
- What chloramphenicol formulation and amounts were actually administered, by which route and at what times? measurement
- Does the exposure history come from administration records, caregiver reports or documented maternal treatment? provenance
Clearance context
Places measured concentrations within developmental and organ-function context.
Accumulation evidence
Retain age, renal and hepatic observations, serial drug measurements and sampling context without imposing an unverified toxic threshold.
- What developmental age and renal or hepatic findings are relevant to interpreting this infant's exposure? measurement
- When were concentrations collected relative to dosing, and what evidence supports accumulation rather than an isolated high sample? measurement
Presentation and differential Organises observed manifestations and evaluates competing or concurrent explanations.
Manifestation timeline
Records the onset and sequence of gastrointestinal, colour, respiratory and circulatory changes.
Observed clinical pattern
Distinguish observed, absent, unassessed and retrospectively reported manifestations.
- Which manifestations were observed, and when did each begin relative to chloramphenicol exposure? measurement
- Which findings were assessed and absent, and which were never assessed? provenance
Competing causes
Maintains alternative explanations alongside drug-toxicity attribution.
Differential evidence
Record evidence for infection-related shock, cardiopulmonary disease, dyshemoglobinemia and other relevant toxic exposures.
- What evidence supports or weakens each alternative explanation for the infant's colour change and deterioration? boundary
- Could the treated infection or another condition coexist with chloramphenicol toxicity? boundary
Severity and urgent response Connects current physiological compromise with documented clinical escalation.
Physiological severity
Tracks circulatory and respiratory compromise without inventing a syndrome-specific severity score.
Deterioration and support
Record serial observations together with respiratory and circulatory support already in use.
- What current observations demonstrate respiratory compromise or impaired circulation, and how are they changing? measurement
- Which findings meet the applicable neonatal escalation protocol, and has the responsible clinician been alerted? action
Exposure cessation and care
Records decisions about further exposure and specialist-led management.
Documented response decisions
Capture the last dose, discontinuation decision, urgent clinical review and links to treatment plans.
- Has chloramphenicol been discontinued, when was the last dose, and who documented the decision? action
- What neonatal or toxicology guidance supports the selected monitoring and treatment, including any proposed enhanced drug elimination? provenance
Resolution and case learning Documents recovery, residual uncertainty and evidence suitable for adverse-reaction review.
Response and outcome
Follows manifestations and concentrations after exposure ends.
Dechallenge and resolution
Record improvement after withdrawal alongside simultaneous interventions and unresolved abnormalities.
- How did manifestations and measured concentrations change after the last dose? measurement
- What evidence supports resolution, and which concurrent treatments limit attribution of improvement to drug withdrawal? boundary
Adverse-reaction record
Preserves a reviewable account for pharmacovigilance and future medication decisions.
Traceable case summary
Assemble exposure, phenotype, assessment and outcome without automatically classifying toxicity as allergy.
- Which source records substantiate the suspected reaction, and which uncertainties must accompany any report? provenance
- What clinician-approved medication alert or adverse-reaction documentation should follow this assessment? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of gray baby syndrome this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Information and virtual systems
- Entry kind
- thing
- Plane
- INF
- Domain
- INF.MED
What it is Filled
Gray baby syndrome is a potentially fatal chloramphenicol toxicity syndrome, classically affecting neonates with immature drug metabolism and clearance, characterized by abdominal distension, gray or cyanotic skin discoloration, and cardiovascular collapse.
In scope
- Chloramphenicol exposure and its temporal relationship to suspected toxicity
- Developmental and physiological factors affecting drug accumulation
- Clinical manifestations, deterioration and recovery
- Diagnostic evidence, competing explanations and attribution confidence
- Syndrome-specific escalation, monitoring and adverse-reaction documentation
Out of scope
- The infant's complete longitudinal health record
- General chloramphenicol chemistry, manufacture and antimicrobial prescribing
- The infection for which chloramphenicol was administered
- Other chloramphenicol adverse effects without this syndrome
- General neonatal shock protocols and the complete intensive-care encounter
Why it exists Filled
Enable an AI agent to recognise suspected gray baby syndrome, assess exposure and clinical deterioration, and support timely clinician-led escalation while preserving diagnostic uncertainty.
Distinguishing features Filled
- Establish a plausible chloramphenicol exposure before attributing gray discoloration or circulatory deterioration to this syndrome.
- Assess the combination and chronology of abdominal distension, pallid cyanosis, respiratory irregularity and circulatory collapse; these are reported manifestations rather than a validated mandatory checklist. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)
- Distinguish elevated chloramphenicol concentrations from the clinical syndrome: a neonatal study reported elevated concentrations in some infants without toxicity. [Primary neonatal study](https://pubmed.ncbi.nlm.nih.gov/6416440/)
- Record whether sepsis, cardiac disease, respiratory disease or dyshemoglobinemia better explains the presentation, and allow concurrent causes.
- Distinguish this acute toxic presentation from isolated hematological adverse effects attributed to chloramphenicol.
What robots and AI may and may not do Filled
Must not
- Diagnose gray baby syndrome in a particular infant.
- Recommend, adjust or stop any medicine dose for a newborn or a pregnant or breastfeeding person.
- Suggest that a sick newborn can wait for home care instead of urgent medical attention.
- Blame parents or named clinicians for a case without evidence.
Only with a human decision
- Any treatment decision for an infant suspected of drug toxicity.
May
- Explain gray baby syndrome and its link to chloramphenicol from reliable medical sources.
- Point parents and carers to a doctor or emergency service when a newborn seems unwell.
- Flag chloramphenicol in a newborn's medication record for clinician review.
Moral aspects Filled
- Newborns cannot speak for themselves; delay or bad advice can cost a life.
- Medication errors in neonates must be reported honestly so others can learn from them.
Who is affected
- Newborn infants
- Parents and carers
- Neonatal clinicians
Owners Filled
Steward
Nobody owns the condition; the treating clinician answers for each patient and medicines regulators for drug safety.
Links to other meta-models Filled
parent
- Q387175 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.gray-baby-syndrome
- Wikidata: Q374186 (https://www.wikidata.org/wiki/Q374186)
Direct properties not applicable Not applicable
- Exposure provenance: Links to medication administration, dispensing or maternal exposure evidence; documented, reported, inferred or unknown
- Developmental age at exposure: Gestational age at birth in weeks and days; postnatal age in days; postmenstrual age in weeks and days
- Administered chloramphenicol exposure: mg per administration, mg/kg per administration, interval in hours, route, formulation and timestamp
- Chloramphenicol concentration: mg/L or equivalent micrograms/mL, with specimen, analyte, collection time and elapsed time since dose
- Clinical trajectory: Suspected evolving toxicity, deteriorating, stabilising, recovering, resolved or unknown; descriptive states rather than validated stages
- Circulatory and respiratory observations: Blood pressure in mmHg, heart and respiratory rates per minute, oxygen saturation in percent, with timestamps and support context
- Attribution status: Suspected, clinician-supported, disputed, excluded or unresolved; assessor and assessment method required
- Terminology mapping: Coding system, edition or release, jurisdiction, identifier, label and mapping relationship; unverified when unresolved
Plane INF: no invented physical properties.
Recognition optional Filled
- Gray or blue skin discoloration can raise suspicion in a newborn with documented chloramphenicol exposure, but it is not specific to this syndrome.
- Abdominal distension accompanying the discoloration can support suspicion while overlapping with other neonatal illnesses.
- A limp appearance and visibly irregular breathing can accompany severe deterioration, but appearance alone cannot establish the diagnosis.
Capabilities and actions required Filled
- Assemble a timestamped exposure-to-deterioration timeline.
- Flag compatible deterioration after chloramphenicol exposure for urgent clinician review.
- Identify missing dose, weight, specimen-timing or competing-diagnosis evidence.
- Compare clinical and concentration trends before and after documented interventions.
- Prepare a traceable suspected adverse-reaction summary for clinician review.
- Link a diagnostic assertion to a verified terminology release while retaining unresolved mappings.
Hazards and failure modes required Filled
- Severe toxicity can progress to cardiovascular collapse and death.
- Confusion with sepsis or other causes of neonatal cyanosis can delay recognition of drug toxicity.
- Failure to identify chloramphenicol exposure can allow the underlying toxic effect to continue.
Standards and interfaces required Filled
- The World Health Organization's ICD-10 category P93 covers reactions and intoxications due to drugs administered to the fetus and newborn, including gray syndrome from chloramphenicol administration.
Context of use required Filled
- Gray baby syndrome is encountered in neonatal medicine and drug safety assessment following chloramphenicol exposure.
- The term helps clinicians describe suspected toxicity involving impaired drug clearance and potentially severe circulatory deterioration.
Sources Filled
- Wikidata item Q374186: gray baby syndrome - identity and sense of the item
- Wikipedia: Gray baby syndrome - general description of the item
Open questions
- Is there a validated contemporary diagnostic definition or severity classification, and which issuing body and version should govern its use?
- What exact ICD-10, ICD-11 and SNOMED CT mappings apply across jurisdictions and releases, including distinctions between adverse effects and poisoning?
- What contemporary incidence or prevalence estimates exist with explicit population, exposure denominator, location and observation year?
- How should neonatal, older-infant and older-patient gray syndrome reports be bounded within this registry entry without creating unsupported separate concepts?
- What evidence supports concentration interpretation and enhanced elimination interventions in affected infants, and how dependent is that evidence on historical case reports?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q374186/spec.json